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ABSTRACT
Importance: The Use of a Multidrug Pill In Reducing
cardiovascular Events (UMPIRE) trial has shown
improved adherence with the use of a polypill strategy
when compared with usual medications for
cardiovascular disease (CVD) prevention. To advance
from efficacy to impact, we need a better
understanding of why and how such a strategy might
be deployed in complex health systems.
Objective: To understand, from the perspective of
UMPIRE trial participants and professionals, how and
why a polypill strategy improves adherence compared
with usual care, why improvement is greater in some
subgroups, and to explore the acceptability of a polypill
strategy among trial participants and healthcare
professionals.
Design, setting and participants: A preplanned
process evaluation, based on qualitative interviews,
was conducted with a subsample of 102 trial
participants and 41 healthcare professionals at the end
of the UMPIRE trial in India and Europe.
Results: Most patients contrasted the simplicity of the
polypill with usual medications that they found
complex and, for many in India, expensive. Patients
with low baseline adherence struggled most with
complex medication lists, and those without
established disease described less motivation to adhere
when compared with people who had already been
diagnosed with CVD; people in the latter group had
already undertaken self-directed measures to adhere to
CVD preventive medicines prior to entering the trial.
Taking medication was one of many adaptations
described by patients; these included dietary changes,
stopping smoking and maintaining exercise. Most
patients liked the polypill strategy, although some
participants and health professionals were concerned
that it would provide less tailored therapy for individual
needs.
Conclusions: Adherence to treatment lists with
multiple medications is complex and influenced by
several factors. Simplifying medication by using a
once-daily polypill is one approach to CVD prevention
that may enhance adherence. Prescribers should also
consider the wide variety of adjustments that
individuals need to make to cope with daily
medication.
INTRODUCTION
The burden of cardiovascular disease (CVD)
is a major global priority.1 Aspirin, statins
and antihypertensive therapy are effective in
reducing cardiovascular events and mortality.
The combined use of these drugs is clearly
indicated in people at high risk of CVD,
especially those who have already suffered a
myocardial infarction or stroke. The majority
of people who could beneﬁt from these
drugs do not have access to them, and
among those who do, adherence is poor.2
Four recent trials3–6 have reported the
impact of a polypill strategy on adherence to
recommended preventive medications in
patients with established CVD (or at high
risk of CVD) in different settings: the Use of
a Multidrug Pill In Reducing cardiovascular
Events (UMPIRE) trial in India and Europe,3
the Kanyini Guidelines Adherence with the
Polypill (Kanyini-GAP) trial in Australia,4 the
IMProving Adherence using Combination
Therapy (IMPACT) trial in New Zealand5
and the Fixed-Dose Combination Drug
for Secondary Cardiovascular Prevention
(FOCUS) trial in Argentina, Brazil, Italy,
Paraguay and Spain.6
Strengths and limitations of this study
▪ A strength of this study is that it included
exploratory interviews with relatively large
numbers of trial participants and professionals,
using a standard interview topic guide.
▪ Interviews were conducted in diverse settings in
the UK and India, with trial participants and
health professionals.
▪ A limitation of this study is that trial participants
and health professionals may have been inclined
to speak positively about the trial. Various mea-
sures were taken to reduce this likelihood includ-
ing confidentiality and anonymity.
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Three of the trials (UMPIRE, Kanyini-GAP and
IMPACT) used similar protocols under the umbrella of
the Single Pill to Avert Cardiovascular Events (SPACE)
collaboration.7 All four trials have shown that administra-
tion of medications as a polypill confers clinically
important improvement in adherence when compared
with usual care. These promising results add weight to
the argument for the wider use of cardiovascular poly-
pills as a preventive strategy, although there remain a
number of key issues to address.8
The three SPACE trials showed greater beneﬁt in
people who were less adherent to cardiovascular medica-
tions at baseline; two trials found a greater beneﬁt in
people at high risk rather than those with established
disease (UMPIRE and Kanyini-GAP) and in smokers
(UMPIRE, and a non-signiﬁcant trend in Kanyini-GAP);
the IMPACT study found a larger effect in younger
people. Polypill discontinuation rates ranged between
22% and 37% after 12–18 months of follow-up.
To improve our understanding of the potential
strengths and limitations of the polypill strategy, we
carried out a process evaluation of the UMPIRE trial.
The trial design has previously been reported.3 9
UMPIRE was a randomised, open-label, blinded end
point clinical trial (clinicaltrials.gov: NCT01057537). It
compared a polypill-based strategy with usual care in
individuals in Europe and India with established CVD or
at high risk of CVD. Participants randomised to the poly-
pill strategy were prescribed one of two polypill formula-
tions: V.1 (aspirin, 75 mg; simvastatin, 40 mg; lisinopril,
10 mg; and atenolol, 50 mg) or V.2 (aspirin, 75 mg; sim-
vastatin, 40 mg; lisinopril, 10 mg; and hydrochlorothia-
zide, 12.5 mg). The polypill was taken once daily.
Participants allocated to usual care continued with their
usual cardiovascular preventive medications. Both arms
of the UMPIRE trial showed improved adherence to
indicated cardiovascular medication (aspirin, statin and
≥2 blood pressure lowering medicines) from baseline,
together with corresponding reductions in blood pres-
sure and low-density lipoprotein cholesterol3 with
improvements signiﬁcantly favouring the polypill group.
By the end of the trial (median follow-up 15 months),
22% of participants in the polypill arm had stopped
taking the pill.
Qualitative process evaluations are increasingly used in
trials involving complex healthcare interventions to
explore health professionals’ and patients’ views of the
intervention, to understand components of an interven-
tion and the way the impact varies among subgroups.10
Process evaluations are particularly useful in multisite
trials where delivery and uptake of interventions may
differ across the sites. Exploring the circumstances inﬂu-
encing improved adherence and clinical outcomes in
the polypill treatment group will provide guidance on
the clinical utility of this strategy and its potential
scale-up.
This paper presents the ﬁndings of a preplanned9
process evaluation examining the barriers and
facilitators to adherence within the two treatment
groups and among subgroups in which the polypill strat-
egy appeared to be particularly effective. Our aim is to
understand key ﬁndings from the UMPIRE trial from
the perspective of participants and professionals,
namely:
A. How and why a polypill strategy for CVD prevention
improves adherence compared with usual care;
B. Why the beneﬁt is greatest in those who have lower
adherence at baseline, those who have yet to have a
cardiovascular event and smokers;
C. Why a signiﬁcant proportion of participants discon-
tinued the polypill during the trial.
In addition, the process evaluation explores the
acceptability of a polypill strategy with trial participants
and healthcare professionals.
METHODS
Study design and sample
INPUT (INterpreting the Processes of the UMPIRE
Trial) is a process evaluation based on qualitative inter-
views of the UMPIRE trial participants and healthcare
professionals at three trial coordinating centres:
Hyderabad and Delhi (India) and London (UK).
Interviews based on a predeﬁned protocol were carried
out at the end of the trial.11
In both countries, a range of health professionals were
identiﬁed locally and invited to an interview. They were
involved in the UMPIRE trial in some way, either as
investigators or by supporting their patients’ participa-
tion. In addition, local health professionals working in
CVD prevention were identiﬁed and invited to be inter-
viewed. More Indian health professional staff members
were included to reﬂect the large number of trial sites
(28 in India compared with 3 in Europe).
For the process evaluation, trial participants of diverse
ages, genders, length of trial participation and treatment
arms were invited. These included some who had dis-
continued the polypill. Interviews were conducted at the
ﬁnal trial visit between February and July 2012; at this
point, the UMPIRE trial results were yet unknown. To
capture the diversity of the Indian trial sites, the partici-
pant interviews took place across a selection of six of
these sites and were conducted in English or appropri-
ate local languages. When interviewers were available,
initially consecutive trial participants were invited for
interview; later on sampling was focused on demo-
graphic groups under-represented in the sample.
Interviews were conducted by two researchers in the
UK and two in India. All interviews were audio-recorded
and transcribed. In India, the transcriptions were trans-
lated from local languages where necessary and the
accuracy of the translation was veriﬁed by multilingual
researchers. Data were analysed using the exploratory
method of grounded theory.12 The methods are
described in detail elsewhere.11 ASM and FW were
responsible for the analysis, and it was supervised by
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HW, ST and SD. It was initially done separately in the
UK and India, and then the two contexts were com-
pared and contrasted. Nvivo V.9.0 was the data manage-
ment software used for the analysis.
RESULTS
One hundred and two trial participants were inter-
viewed, 50 from the UK and 52 from India; 7 and 2 par-
ticipants, respectively, declined to take part in the
interviews. Data saturation was reached at this point.
The characteristics of the interviewed participants are
described in table 1.
Forty-two health professionals were also interviewed.
The 26 Indian health professionals interviewed came
from 11 separate sites and included: 16 cardiologists, 8
other physicians (1 neurologist, 1 endocrinologist, 6
general practitioners) and 2 research coordinators. The
15 UK health professionals interviewed included: 5 car-
diologists, 1 neurologist, 1 elderly care physician, 2
general practitioners, 3 specialist nurses and 2 pharma-
cists. In the UK and India, respectively, 26 and 1 health-
care professionals declined participation or did not
respond to the invitation.
Interviews with trial participants and professionals
revealed a wide range of inﬂuences on adherence in the
context of the trial and more generally, many of which
shed light on the overall results. A model of these
factors is presented in ﬁgure 1, grouping them into indi-
vidual, intervention, trial context and wider social and
cultural levels. Table 2 lists a selection of quotes from
the interviews highlighting the themes discussed below.
Adherence is better with the polypill than with usual care
Overall, the improved adherence favoured the polypill,
even in this trial population with relatively high baseline
adherence.3 Adherence and motivation can be attribu-
ted to the convenience of a simpliﬁed regimen. This is
best understood in relation to the challenges of the alter-
native polypharmacy. This convenience did not quantiﬁ-
ably improve adherence if participants were already
competent adherers at baseline, but they uniformly
reported that the polypill made adherence easier. The
polypill was preferred over usual care by the majority of
the participants who were interviewed (quote 1).
Convenience was attributed to the polypill in several
ways including reduction in the number of pills taken
per day, a decrease for some in the frequency of times a
day pills were taken and fewer packages to transport and
store (quote 2).
Adhering to the correct dose was made easier by the
packaging of the polypill, which came in blister packs
containing 1 week of tablets labelled with the days of the
week. The polypill group had to return empty blister
packs to the trial centre which may also have inﬂuenced
reported adherence and made participants aware that
others were observing their behaviour. The novelty of
the polypill was also proposed as a positive inﬂuence on
adherence (quote 3).
There was a cost differential between arms of the
study for some participants, but overall in the UMPIRE
trial there was no difference in adherence between
those who were and were not exempt from medication
or prescription charges.3 Nevertheless, interviews with
individual participants and professionals in India high-
lighted cost as an important factor due to the signiﬁcant
expense incurred by some patients in the usual care
group. In contrast, most UK participants were either
exempt from prescription charges or on a ﬁxed
payment scheme for all their prescriptions. While some
participants in India were exempt from charges through
welfare or insurance systems, for others it was a major
barrier. One health professional highlighted this,
describing an encounter with a patient who had stopped
taking anticoagulants after valve surgery (quote 4).
Free treatment was an incentive in some circumstances
as well as a likely beneﬁt of the polypill strategy itself
(quote 5). Participants in India gave many examples of
the difﬁcult decisions they had to take if they were paying
for multiple pills or other healthcare interventions.
The polypill works best in people with poor adherence at
baseline
The UMPIRE trial reported a higher impact in those
who were less adherent at baseline. Such participants
typically showed a >3-fold improvement in adherence if
Table 1 Description of the interviewed trial participants in India and UK
UK India
Polypill Usual care Total Polypill Usual care Total
Number of participants (%) [number Of
discontinuing polypill]
25 (50) [9] 25 (50) 50 31 (60) [2] 21 (40) 52
Mean age in years [SD] 70 [9.4] 69 [11.8] 69 [10.6] 57 [10.5] 55 [11.5] 57 [10.9]
Male 20 (80%) 20 (80%) 40 (80%) 27 (87%) 20 (95%) 47 (90%)
Current smokers 2 (8%) 3 (12%) 5 (10%) 1 (3%) 0 (0%) 1 (2%)
Number of participants adherent at baseline (%) 17 (68%) 18 (72%) 35 (70%) 13 (42%) 12 (57%) 25 (48%)
Diabetes mellitus 8 (32%) 5 (20%) 13 (26%) 11 (35%) 5 (24%) 16 (31%)
Established CVD 17 (68%) 19 (76%) 36 (72%) 27 (87%) 17 (81%) 44 (85%)
CVD, cardiovascular disease.
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they were randomised to the polypill.3 This reﬂects the
difﬁculties some people have with taking multiple medi-
cations; those who struggle are likely to beneﬁt most
from a simpliﬁed regimen.
Participants described how medications were some-
times missed, delayed, taken by accident, deliberately
omitted or taken in excess. Multiple factors appeared to
contribute to this including side effects, cost, changes in
routine, travelling, tiredness, household roles, shift work,
time constraints, forgetfulness, illiteracy and running out
of supplies. Some participants indicated that more
complex medication regimes increased the chances that
they would diverge from their prescribed regimen. For
people with such difﬁculties, and who are therefore less
adherent at baseline, the polypill can have a greater
impact than for those who are already highly adherent.
Participants in the UK often expressed conﬁdence that
they never missed medication while using the polypill
and emphasised their successful adherence by returning
their empty blister packs at their scheduled visits.
UK participants discussed trying to overcome the com-
plexity of their usual daily medicine regimes by develop-
ing personal strategies for adherence, for example,
distributing pills in to a pill box, keeping a written
record of what medications they had taken or keeping
their medications on a visible surface to remind them.
Additional strategies were reported in India. Many
Indian participants were illiterate and described the
challenge of having to identify pills. They often relied
on support for identifying tablets or memorised the
colour and shape of their medications. The polypill was
sometimes described as larger than other tablets and
harder to swallow but this feature also made it more dis-
tinctive (quotes 6 and 7).
The polypill has greater adherence impact in those
without established CVD
The UMPIRE trial found the polypill to have a greater
impact in those at high risk of CVD than in those with
established disease. Health professionals highlighted
the issues of adherence for those at high risk (quote 8
and 9).
Most interviewees were highly motivated to take their
medication, and those with established disease had less
room for improvement as they had already developed
effective strategies to take their multiple pills. In the UK,
several patients described relatively subtle symptoms
when they had been diagnosed with myocardial infarc-
tions or other manifestations of vascular disease, and
they were anxious about not recognising future events.
Figure 1 Model of medication adherence influences during the UMPIRE trial. The model demonstrates the abstracted themes
that from the analysis of interviews were deemed influential to adherence in a trial context. This model may be useful for
researchers designing future trials regarding adherence, because it outlines the multiple complex levels of influences on
adherence that could be associated with a trial context. CVD, cardiovascular disease; HCP, healthcare professional; UMPIRE,
Use of a Multidrug Pill In Reducing cardiovascular Events.
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Table 2 Selection of quotes from the interviews
Quote 1 Obviously, convenience-wise, it[the polypill] was a lot easier because I think I take about six or seven tablets a
day…and, obviously, with the polypill, it makes it a lot easier. So, there are only a few tablets to remember. [Trial
participant, UK]
Quote 2 I have a bag with all my pills and…quite often, half way through taking my pills, I get disturbed, a phone might
ring, my wife speaks to me, I then have to think, well did I actually take a pill from the package I’m holding…and I
can’t remember…with the polypill it wouldn’t have mattered so much. It would have been less pills and it’s much
easier to know…because it’s just a lovely packet, you can tell, normally when you have taken the pill or not.
Because, you know, there’s a big hole left if you have taken it, whereas with the other pills, you know I’m taking
from different ends, I ignore the days on the back and things like that. [Trial participant, UK]
Quote 3 In my view, there is a small flaw in the trial, because the trial is looking for compliance and adherence. Any
person who is given a study drug is likely to be more adherent, more compliant. Any person who is asked to
continue the same old drug is likely to be less compliant or at least less interested in the trial. [Cardiologist, India]
Quote 4 He stopped[anticoagulants] for eight months…we told him…it doesn’t cost much, maybe 5 rupees, 10 rupees. If
you don’t have money, you can skip your dinner or lunch, but don’t skip this medicine. So sometimes we use very
emphatic statements like that to tell the importance of these medicines. [Cardiologist, India]
Quote 5 When I came here for a check-up…they told me that there is going to be a lottery for drugs…There will be one
capsule which combines 3–4 drugs and rest will be prescribed to me. It will reduce my expenses. They gave 5–6
months’ worth of drugs in one instalment and then for 5–6 months in the second…the biggest benefit is that I do
a job and this saved me money. I used to buy medicines worth 1000 rupees from the market, but after this, I had
to buy medicines worth only 300–400 rupees. [Trial participant, India]
Quote 6 I have come to recognize them over time. For example, one capsule has a red stripe; there is a white pill that I
now know that I have to take again in the morning. There is a white capsule that I have to take in the night. [Trial
participant, India]
Quote 7 “Then this is 1 tablet, that is 4, it is easier to have a single tablet…yes, I can’t read, I used to recognize them…
yes, by the colour. Sometimes I could make it out also…when I had to buy from the market…I took the medicine
that I had to take in the evening, then had it again…this happened a couple of times. [Trial participant, India]
Quote 8 …if they’ve not had a heart attack then really they feel healthy. And most people don’t like taking loads of
things…[Cardiologist, UK].
Quote 9 If someone’s risks are that high, I think doctors will want to fine tune it[CVD medication] themselves…and if risks
aren’t that high, I don’t think you’ll get long term compliance…with patients…until you have made it clear that this
is a long term strategy, there’s no point…they go away and take it and think, oh I don’t want to. So I think…taking
time to start people on medication is really, really important…understanding what it’s all about. So people aren’t
afraid that they’re turning into grandma by taking tablets at 40 years old. [General Practitioner, UK]
Quote 10 …it’s an opportunity for me to be monitored if you like because I suppose when I first had the heart attack I was
obviously in hospital then had some therapy afterwards. Once that was finished it was sort of “Here are your pills,
off you go and get on with it”. You got all the advice and everything else and stuff like that. But then after a while I
remember going to the doctor about something completely different but asked the question: “What happens
now?” “Am I monitored yearly or what happens.” “Who looks after me?” That was initially soon after the heart
attack. So I just thought it’s[trial participation] a good opportunity to get an idea of how I’m doing but then it’s also
of some benefit to you guys. So it benefits both of us really. [Trial participant, UK]
Quote 11 I always believed before taking these that I would be the sort of person—because before having the heart attack
for many years I was diagnosed as having high blood pressure, I was forgetful so I would sometimes go days
without taking the pills. But since having the heart attack: no, I’ve become very regimented with it. So I don’t think
I’ve ever forgotten even if we go on holiday. I’ve got a pill box and it’s all set out. [Trial participant, UK]
Quote 12 I don’t forget. It has become my daily routine for the last 1¾ years. I fear that if I don’t take the medicine, the pain
will start again or I will become breathless. [Trial participant, India]
Quote 13 They may not be concerned about taking the medicine. This could be the reason. I start worrying if I don’t take
my medicine. So, I don’t forget it. If they don’t feel pain, they become careless. [Trial participant, India]
Quote 14 I think these are all psychosocial problems. Anybody who is taking too much alcohol, too much smoking,
something is wrong with his mind; his training has been negative or something. He knows that smoking is bad but
still does it, they are less compliant. [Cardiologist, India]
Quote 15 I take a multivitamin when I’m working nights…well, you just don’t eat as well when you’re working the night
shift…you have to rely on things like ready meals…believe me. Everybody says, “Oh, no, you could make a good
dinner and take it with you.” No, no, no! It just doesn’t happen on nights…I work seven nights in a row and some
of them are 12-hour shifts and when you go home, you’re tired. You’re not going to start doing that. [Trial
Participant, UK]
Quote 16 The day there is tension I smoke. The day I give up smoking, God willing I will not need to have medicines. [Trial
participant, India]
Continued
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This anxiety enhanced medication adherence and life-
style modiﬁcations. It also motivated them to take part
in research (quote 10).
Those UK participants with established CVD had
attended education and cardiac rehabilitation pro-
grammes and often participated in the trial to have their
health monitored (quote 11).
In India, the distinction between primary and sec-
ondary prevention was unclear in many interviews;
some patients appeared to take their medications to
alleviate symptoms rather than prevent future problems
(quote 12).
There was variation in understanding of medication in
both countries. Some participants could explain the
purpose of each medication including the preventive
role. Some believed that the polypill was for symptom
relief, and others took the recommended medication
without wanting to know the indication and placing trust
in their doctor.
It is likely that the greater improvement observed in
the trial in those without established disease compared
with those with established disease was that there was
less scope for the intervention to add to the higher
underlying motivation in those with the experience of a
cardiovascular event and diagnosis (quote 13).
The polypill having greater adherence impact in smokers
The ﬁnding that the polypill had more of an impact in
smokers was difﬁcult to explore in detail as few smokers
were recruited. Many participants had stopped smoking
following a diagnosis of CVD. Overall, in the trial, 74%
of ‘ever smokers’ were not current smokers.3 In the UK,
interviewees who were current smokers appeared reluc-
tant to discuss their smoking habits. In India, health pro-
fessionals suggested that those who continued to smoke
were unusual (quote 14).
A UK participant, who continued to smoke after
having a stroke, described some of the structural difﬁ-
culties he faced in adopting healthy behaviours. He
talked of taking medication and vitamin supplements
to make up for unhealthy lifestyle factors such as poor
diet and work stress (quote 15). People have different
strategies for managing their health such as uncertain
future risks, and those who smoke may be more moti-
vated to offset this risk by taking a preventive polypill.
A patient from India indicated a belief that pill taking
counteracted the negative effects of smoking (quote
16). Participants in both countries described other
approaches to managing their health including homoe-
opathy, Ayurvedic therapy, changes in diet and
exercise.
Acceptability of a polypill strategy and reasons for
discontinuation
In the UK and India, there was support from patients
and some healthcare professionals for the polypill strat-
egy due to its simplicity and lower cost (quote 17).
However, one limitation to the polypill is the relatively
high rate of discontinuation (quote 18). Discontinuation
was a consequence of side effects or medical instruc-
tion,3 and partly reﬂected the limited variety of polypill
versions available. In the UK, some participants who dis-
continued it said that if a polypill particularly suitable
for them was available, they would prefer it to usual
care. The polypill was not favoured by one participant in
the usual care group who explained that she would not
want to be on a polypill if it meant she was advised to
take a higher dose of a medicine than was absolutely
necessary.
Health professionals anticipated greater adherence
through simpliﬁcation of medication but had concerns
about the perceived inﬂexibility of prescribing inherent
to a polypill. Several commented that the components
and doses in the available polypill version were not
those recommended by the current guidelines. Many
health professionals felt that they would need to be con-
vinced by evidence that a polypill strategy was associated
with better clinical outcomes than taking more persona-
lised doses of a range of medications.
DISCUSSION
This paper describes the views and experiences of 102
UMPIRE trial participants and 41 health professionals in
India and the UK to help interpret the trial ﬁndings
and to understand why adherence favoured the polypill
and speciﬁc subgroups. We also sought trial participants’
and health professionals’ views about the acceptability of
a polypill strategy. The study used the exploratory
method of grounded theory to interpret the interview
data, leading to a proposed model of the inﬂuences on
medicine adherence in the trial. This model can be
taken into account when designing future interventions
of this nature.
We have shown that the polypill is preferable primarily
because usual care is complex and, for some groups,
particularly in India, expensive. Participants’
Quote 17 Well most of the research shows that roughly I think a third of patients…take it if at all…a third take it badly and a
third take it correctly…the best compliance is with an informed patient and once daily medication with as fewer
drugs as possible, so I can see the attraction of the polypill. [General practitioner, UK]
Quote 18 Sometimes I am having side effects because of your capsule…cough only…we will use only 25 every month, in
that 25 also we will drop [skip] five [or] six, but it will stop. But when it stops I will continue again…[Trial
Participant, India]
Table 2 Continued
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descriptions of the challenges they faced with usual care
involving multiple pills over the course of the day reveal
the importance of simpliﬁed regimens. Strategies to aid
adherence before the trial or for those in the usual care
arm included the use of pill dispensers, record keeping
and support from family members. Some groups
manage the complex regimens better than others and
this seems to explain the greater potential improvement
with the polypill strategy for those who are not adherent
at baseline. In some populations, high levels of illiteracy
add to these challenges, with people struggling to
remember instructions for pills of different size and
colour at various times of the day. Unsurprisingly, those
with lower motivation, including those who have not
been diagnosed with a cardiovascular condition but
rather told that they are at increased risk sometime in
the future, are less likely to adhere to these complex
regimens. The greater beneﬁt in smokers and in those
who had not yet had a cardiovascular event appears to
be linked to complex motivations for including medica-
tion as part of a wider strategy for healthy living. We
found many practical obstacles to adherence and a poly-
pill appears to make it easier for some groups to over-
come these.
This process evaluation revealed major differences
between the process and context of the trial in the UK
and India, even though the trial as a whole did not show
a signiﬁcant difference in impact on adherence between
the two countries. In India, the free provision of medica-
tion in the polypill arm was a prominent inﬂuence
described by participants and professionals in relation to
improved adherence; in contrast, cost did not appear to
be a major issue in the context of free or reduced price
medicines within the UK National Health Service
(NHS). The various reported reasons for adherence and
non-adherence were consistent with factors reported in
the literature6 13 14 including convenience through sim-
pliﬁcation of medication schedules and clear
packaging.6 15
We used exploratory interviews to look in detail at the
context of the trial in each country, prior to knowing
the trials result. Once the trial results were known, we
then formulated research questions and further inter-
preted the interviews. Therefore, our process evaluation
collected information about trial context at the time of
the trial, without either the researcher or the participant
being inﬂuenced by the trial results. However, not
having the results when undertaking the interviews
limited the ability to probe for speciﬁc results.
Participants interviewed in India were on average
younger than those interviewed in the UK; however, this
reﬂects the differences in the UMPIRE trial populations
and is reﬂective of the earlier onset of CVD in India
compared with the UK.16 The strength of this evaluation
is that it included interviews with relatively large
numbers of trial participants and professionals, using a
standard interview topic guide. There are limitations to
this work. Participants in the UMPIRE trial, and those
who took part in these interviews, had higher than
average adherence at baseline adherence, but the gener-
alisability of these ﬁndings on adherence to CVD pre-
vention outside the context of a clinical trial setting is
uncertain. Furthermore, the polypill group returned
used blister packs to the trial centre, whereas the usual
care group did not and this may have inﬂuenced partici-
pants’ behaviour.17 Including only one of the three
European countries means the results are less generalis-
able, but focusing on one European site in greater
depth allowed a more meaningful comparison with
India. There were no systematic differences between
those health professionals who participated, declined or
failed to respond.
The process evaluation may have been subject to
social desirability bias, with trial participants and health
professionals being inclined to speak positively about
the trial. Various measures were taken to reduce this
likelihood; the study was identiﬁed as being funded sep-
arately and participants were reassured of conﬁdentiality
and anonymity, that there were no right or wrong
answers and that all views were respected.
CONCLUSION
This analysis shows that adherence to medication regi-
mens is complex and inﬂuenced by a wide range of
factors. Simplifying regimens through once-daily medica-
tion is one key part of improving adherence, but many
other factors including access, cost and motivation of
professionals and patients must also be addressed.
Further studies of a polypill strategy for CVD prevention
should ensure that data are collected on these broader
factors, and the impact considered as part of a complex
intervention to reduce the burden of non-
communicable disease. In extending the use of a CVD
polypill-based preventive strategy to other settings, pol-
icymakers should capitalise on its main strengths in
terms of dosing convenience and potential advantage in
terms of cost, by targeting its use in high-risk popula-
tions where the greatest gains can be achieved.
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